---
document_datetime: 2023-09-21 19:09:33
document_pages: 15
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/novonorm-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: novonorm-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 11.5969496
conversion_datetime: 2025-12-23 06:04:33.999515
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## NovoNorm

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0090               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 06/09/2017                          |                                             | Labelling                        |           |
| WS/0951              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 26/05/2016                          | 28/04/2017                                  | SmPC                             |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IG/0649            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 11/01/2016   | n/a        |                       |                                                                                                                                                                |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2618/ 201412 | Periodic Safety Update EU Single assessment - repaglinide                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 24/09/2015   | 19/11/2015 | SmPC, Annex II and PL | Please refer to NovoNorm-PSUSA/00002618/201412 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IG/0584            | B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                              | 24/07/2015   | n/a        |                       |                                                                                                                                                                |
| WS/0658            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To update the Product Information to the latest QRD template version 9.0. In addition, minor linguistic and editorial changes have been made in section 4.2 and 4.6 of the SmPC. Finally, linguistic amendments to the following languages have been perfomed: BG, CS, DA, DE, ES, ET, FI, FR, HR, LT, NO, PL, RO, SK and SV. C.I.z - Changes (Safety/Efficacy) of Human and | 22/01/2015   | 19/11/2015 | SmPC, Annex II and PL |                                                                                                                                                                |
| N/0084             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                           | 30/07/2013   | 19/11/2015 | PL                    |                                                                                                                                                                |
| IG/0280            | C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 17/04/2013   | n/a        |                       |                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|           | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                           |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0264   | B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                           | 04/02/2013 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IG/0218   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                        | 20/09/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| WS/0266/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                 | 19/07/2012 | 19/07/2012 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| WS/0223   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.5 of the SmPC in order to include a new drug-drug interaction with deferasirox. Section 2 of the Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to delete glycerol from the list of excipients listed in section 3 | 15/03/2012 | 20/04/2012 | SmPC, Annex II, Labelling and PL | The CHMP introduced updated information on a drug-drug interaction with deferasirox, a weak moderate CYP2C8 inhibitor: 'In an interaction study with healthy volunteers, co- administration of deferasirox (30 mg/kg/day, 4 days), a weak moderate inhibitor of CYP2C8 and CYP3A4, and repaglinide (single dose, 0.5 mg) resulted in an increase in repaglinide systemic exposure (AUC) to 2.3-fold (90% CI [2.03-2.63]) of control, a 1.6-fold (90% CI [1.42-1.84]) an |

<div style=\"page-break-after: always\"></div>

|           | of the carton labelling and to make editorial changes throughout the PI. In addition, the MAH took the opportunity to delete the list of local representatives in the Package Leaflet for Prandin only. Furthermore, the PI is being brought in line with the latest QRD template version 8. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            |     | increase in Cmax of 62%, and a small, significant decrease in blood glucose values. Since the interaction has not been established with dosages higher than 0.5 mg for repaglinide, the concomitant use of deferasirox with repaglinide should be avoided. If the combination appears necessary, careful clinical and blood glucose monitoring should be performed (see section 4.4). If repaglinide and deferasirox are used concomitantly, consider decreasing the dose of repaglinide and perform careful monitoring of blood glucose levels.'   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0106/G | This was an application for a group of variations. B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding                                                                        | 20/10/2011 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IG/0068   | B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site                                                                                                                                                                                                                                                                                                                                                      | 11/05/2011 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IG/0021   | B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                       | 12/10/2010 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| IA/0077   | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 14/01/2009   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0074   | Update of sections 4.5 and 4.8 of the Summary of Product Characteristics (SPC) with new safety information regarding the hepatic uptake of repaglinide and the drug-drug interaction between repaglinide and ciclosporin, as requested by the CHMP at the time of the second renewal of the Marketing Authorisation (EMEA/H/C/187/R/73). Relevant sections of the Package Leaflet (PL) were updated accordingly. Furthermore, minor corrections have been made in the PL to ensure compliance with the latest QRD template. Update of Summary of Product Characteristics and Package Leaflet | 20/11/2008   | 17/12/2008 | SmPC and PL | At the time of the second renewal of the Marketing Authorisation (MA) of Novonorm (EMEA/H/C/187/R/73), the Marketing Authorisation Holder committed to submit a type II variation to update sections 4.5 and 4.8 of the Summary of Product Characteristics (SPC) with information regarding the hepatic uptake of repaglinide and the drug- drug interaction between repaglinide and ciclosporin (an immunosuppressive drug). Initially, data indicated that repaglinide was metabolised predominately by cytochrome P3A4 (CYP3A4). However, subsequent in vitro studies and clinical studies in healthy volunteers indicate that repaglinide is metabolised predominantly by CYP2C8, and to a lesser extent also by CYP3A4, but that the relative contribution of CYP3A4 can be increased if CYP2C8 is inhibited. Consequently, metabolism, and therefore clearance of repaglinide, may be altered by drugs which influence these CYP-450 enzymes via inhibition or induction. More recent research shows that repaglinide is also a substrate for active hepatic uptake via the organic anion transporting protein OAT1P1B. Furthermore, drugs that inhibit OAT1P1B, alone or concomitantly with inhibition of CYP3A4 and/or CYP2C8, may have a potential to increase plasma concentrations of repaglinide. This information was included in the SPC. Based on the above pharmacokinetic findings in connection with ciclosporin, known to inhibit OATP1B1 as well as CYP3A4, a statement regarding the effects of ciclosporin on |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                      |            |            |                        | repaglinide pharmacokinetics was included in the SPC. A similar wording regarding the concomitant use of trimethoprim with repaglinide was also included taking into account the larger increase in exposure observed with trimethoprim. Furthermore, information regarding the possible increased risk of hypoglycaemia due to interactions was included in section 4.8 of the SPC.   |
|---------|------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0075 | IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release | 24/10/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0076 | IA_32_a_Change in batch size of the finished product - up to 10-fold                                 | 08/10/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                        |
| R/0073  | Renewal of the marketing authorisation.                                                              | 30/05/2008 | 23/07/2008 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0072 | Update of or change(s) to the pharmaceutical documentation                                           | 21/02/2008 | 26/02/2008 |                        |                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0071 | Change(s) to the manufacturing process for the active substance                                      | 21/02/2008 | 26/02/2008 |                        |                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0070 | IA_05_Change in the name and/or address of a manufacturer of the finished product                    | 05/11/2007 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0069 | IB_33_Minor change in the manufacture of the finished product                                        | 09/08/2007 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| II/0068   | Update of sections 4.4, 4.8 and 5.1 of the SPC to reflect the results of an epidemiological Study (cardiovascular outcomes study). Other minor changes have been introduced throughout the product information. Update of Summary of Product Characteristics, Labelling and Package Leaflet   | 24/05/2007   | 29/06/2007   | SmPC, Annex II, Labelling and PL   | The MAH undertook an epidemiological study to quantify the potential cardiovascular risk of repaglinide. The purpose of this study was to compare the rate of major cardiovascular events among type 2 diabetic patients treated with repaglinide as monotherapy or as part of combination therapy compared with type 2 diabetic patients, who use sulfonylureas and with other patients who use non-insulin secretagogue metformin or acarbose pharmacotherapy. Based on the study results the SPC was updated to reflect that and that in an epidemiological study, a higher incidence of acute coronary syndrome (e.g. myocardial infarction) was reported in repaglinide treated patients as compared to sulfonylurea treated patients. However, the CHMP acknowledged that causality of the relationship remains uncertain.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0067   | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                                          | 12/07/2006   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0066   | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                                          | 12/07/2006   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0064   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                                                                                                                                                                       | 28/10/2005   | 28/10/2005   | SmPC, Labelling and PL             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0062   | IB_25_a_01_Change to comply with Ph. - compliance with EU Ph. - active substance                                                                                                                                                                                                              | 28/06/2005   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0063   | IA_13_a_Change in test proc. for active substance - minor change                                                                                                                                                                                                                              | 09/06/2005   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| II/0061   | Update of or change(s) to the pharmaceutical documentation                                                                                                                                                                                                                                                                                                                                                   | 26/05/2005   | 01/06/2005   |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0057   | Update of or change(s) to the pharmaceutical documentation                                                                                                                                                                                                                                                                                                                                                   | 21/04/2005   | 12/05/2005   |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0059   | IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)                                                                                                                                                                                                                                                                                                                     | 30/03/2005   | n/a          |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0060   | IA_13_a_Change in test proc. for active substance - minor change                                                                                                                                                                                                                                                                                                                                             | 03/03/2005   | n/a          |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0058   | IB_33_Minor change in the manufacture of the finished product                                                                                                                                                                                                                                                                                                                                                | 02/03/2005   | n/a          |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0056   | IB_10_Minor change in the manufacturing process of the active substance IB_12_b_02_Change in spec. of active subst./agent in manuf. of active subst. - test parameter                                                                                                                                                                                                                                        | 02/03/2005   | n/a          |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0052   | Update of Summary of Product Characteristics (sections 4.4 and 4.5) and Package Leaflet with recent information on CYP2C8 metabolism and co- administration of trimethoprim and rifampicin. In addition, barbiturates and carbamazepine have been included with the list of substances that reduce the hypoglycaemic effect of repaglinide. Update of Summary of Product Characteristics and Package Leaflet | 15/12/2004   | 02/02/2005   | SmPC and PL | Based on recent interaction studies the MAH applied for an update of section 4.4 and 4.5 of the SPC to reflect information on CYP2C8 metabolism and co-administration of trimethoprim and rifampicin. Concerning the interaction between repaglinide and trimethoprim, the CHMP concluded that co-administration of trimethoprim and repaglinide increased the exposure of repaglinide without affecting blood glucose levels in healthy volunteers. Only dosages of 0,25 mg repaglinide and 320 mg trimethoprim (minimal therapeutic dose) have been used in the interaction study. The CHMP was of the opinion that, since the safety profile of this combination has not |

<div style=\"page-break-after: always\"></div>

|         |                                                                                         |            |     |                        | been established with dosages higher than 0.25 mg for repaglinide and 320 mg for trimethoprim, the concomitant use of trimethoprim with repaglinide should be avoided. If necessary, a close clinical and biological monitoring should be recommended. The CHMP concluded that this information should be described in the SPC. Regarding the concomitant use of repaglinide and rifampicin, the CHMP considered that co-administration of rifampicin and repaglinide produces a markedly decreased exposure of repaglinide, especially after end of treatment with rifampicin (effect of induction only). Therefore there is a risk for lack of efficacy. Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose adjustment which should be based on carefully monitored blood glucose concentrations. The CHMP concluded that this information should be described in the SPC. In addition the barbiturates and carbamazepine have been included with the list of substances that reduce the hypoglycaemic effect of repaglinide in section 4.5 of the SPC.   |
|---------|-----------------------------------------------------------------------------------------|------------|-----|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0055 | IA_05_Change in the name and/or address of a manufacturer of the finished product       | 01/02/2005 | n/a |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0054 | IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms | 17/01/2005 | n/a |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0053 | IA_47_c_Deletion of a pack size(s)                                                      | 31/08/2004 | n/a | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IA/0051   | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 29/06/2004   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0050   | The Marketing Authorisation Holder applied to update section 4.8 of the Summary of Product Characteristics (SPC) as requested by the CPMP following the renewal of NovoNorm. The changes concern the deletion of a sentence regarding liver disorders and the causal relationship with repaglinide, the inclusion of a wording regarding third party assistance in case of severe hypoglycaemia and the inclusion of a wording regarding vasculitis in section 4.8 of the SPC. In addition the MAH applied to implement minor linguistic improvements in the SPC and took the opportunity to make a correction in the Annex II. | 26/02/2004   | 31/03/2004 | SmPC and Annex II | The MAH was requested to update section 4.8 of the SPC following the assessment of the renewal, which included the 7th PSUR for repaglinide. The MAH was requested by CHMP to delete the following text concerning liver disorders in section 4.8 of the SPC: \"_however, other causes were implicated in these cases and a causal relationship with repaglinide has not been established.\" Furthermore, the MAH was requested to bring the SPC in line with the statement in the company core data sheet concerning the need for third party intervention (concerning hypoglycaemia) and to add the term vasculitis.\" |
| IA/0047   | IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/12/2003   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0049   | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 08/12/2003   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0048   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                            | 08/12/2003   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| I/0046    | IB_10_Minor change in the manufacturing process of the active substance IB_12_b_02_Change in spec. of active subst./agent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 03/12/2003   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|         | in manuf. of active subst. - test parameter                                                                                                                                                                                                    |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0045 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                               | 26/06/2003 | 08/10/2003 | SmPC and PL                      | Update following an Urgent Safety Restriction (USR), related to a newly identified interaction between repaglinide and gemfibrozil. A scientific publication demonstrated that gemfibrozil raised the AUC of repaglinide 8.1 fold and prolonged its half-life 3 times. The combination of gemfibrozil and itraconazole resulted in an even more pronounced effect: AUC was raised 19.4-fold, and half-time increased from 1.3 to 6.1h. The MAH in addition searched their safety database and identified five serious and four non-serious reports of hypoglycaemia during treatment with repaglinide and gemfibrozil. Concomitant use was consequently contraindicated and sections 4.3 and 4.5 of the SPC and sections 6 and 7 of the Package Leaflet updated accordingly. |
| R/0044  | Renewal of the marketing authorisation.                                                                                                                                                                                                        | 22/05/2003 | 01/08/2003 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| I/0043  | 15_Minor changes in manufacture of the medicinal product                                                                                                                                                                                       | 21/11/2002 | 26/11/2002 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0035 | Update of Summary of Product Characteristics (section 4.5) and Package Leaflet to reflect new available information on the concomitant use of repaglinide and clarithromycin. Update of Summary of Product Characteristics and Package Leaflet | 30/05/2002 | 09/09/2002 | SmPC and PL                      | Based on a published study and adverse event reports the MAH applied for an update of section 4.5 of the SPC and section 7 of the Package Leaflet to reflect information regarding the concomitant use of repaglinide and chlarithromycin. The CHMP concluded that the data showed that co-administration with clarithromycin, a mechanism based inhibitor of CYP3A4, with repaglinide may result in increased exposure and enhance the bloodglucose-lowering effect of repaglinide. In an interaction study in healthy                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|        |                                                                                                                                                                 |            |            |      | volunteers, co-administration of 250 mg clarithromycin increased the repaglinide (AUC) by 40% and Cmax by 67% and increased the mean incremental AUC of serum insulin by 51% and the maximum concentration by 61%. The exact mechanism of this interaction is not clear.   |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I/0042 | 01_Change in the name of a manufacturer of the medicinal product 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process | 18/04/2002 | 30/04/2002 |      |                                                                                                                                                                                                                                                                            |
| I/0041 | 12a_Change in specification of starting material/intermediate used in manuf. of the active substance                                                            | 18/04/2002 | 30/04/2002 |      |                                                                                                                                                                                                                                                                            |
| I/0040 | 24_Change in test procedure of active substance                                                                                                                 | 18/04/2002 | 30/04/2002 |      |                                                                                                                                                                                                                                                                            |
| I/0039 | 24_Change in test procedure of active substance                                                                                                                 | 18/04/2002 | 30/04/2002 |      |                                                                                                                                                                                                                                                                            |
| I/0038 | 24_Change in test procedure of active substance                                                                                                                 | 18/04/2002 | 30/04/2002 |      |                                                                                                                                                                                                                                                                            |
| I/0037 | 24_Change in test procedure of active substance                                                                                                                 | 18/04/2002 | 30/04/2002 |      |                                                                                                                                                                                                                                                                            |
| I/0036 | 24_Change in test procedure of active substance                                                                                                                 | 18/04/2002 | 30/04/2002 |      |                                                                                                                                                                                                                                                                            |
| I/0032 | 20_Extension of shelf-life as foreseen at time of authorisation                                                                                                 | 31/10/2001 | 28/01/2002 | SmPC |                                                                                                                                                                                                                                                                            |
| I/0033 | 12a_Change in specification of starting material/intermediate used in manuf. of the active substance                                                            | 26/10/2001 | 05/11/2001 |      |                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| II/0031   | Update of Summary of Product Characteristics (sections 4.5 and 4.8) to include information on hypoglycaemia following the use of repaglinide with other antidiabetic agents. Update of Summary of Product Characteristics                                                                                                                         | 31/05/2001   | 17/09/2001   | SmPC        | Following the assessment of the fourth PSUR the CHMP requested the MAH to update section 4.5 and 4.8 of the SPC to include information on interaction with other antidiabetic agents. The following information was added to section 4.8 of the SPC: \"During post marketing experience, cases of hypoglycaemia have been reported in patients treated in combination with metformin or thiazolidinedione\".   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0026   | - Update of Summary of Product Characteristics (section 4.3) and Package Leaflet based on the results of a renal efficacy and safety study. - Update of Summary of Product Characteristics (section 4.8) and Package Leaflet with regards to information on hepatic dysfunction. Update of Summary of Product Characteristics and Package Leaflet | 16/11/2000   | 05/03/2001   | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                              |
| I/0025    | 25_Change in test procedures of the medicinal product                                                                                                                                                                                                                                                                                             | 26/04/2000   | 04/05/2000   |             |                                                                                                                                                                                                                                                                                                                                                                                                              |
| I/0024    | 25_Change in test procedures of the medicinal product                                                                                                                                                                                                                                                                                             | 26/04/2000   | 04/05/2000   |             |                                                                                                                                                                                                                                                                                                                                                                                                              |
| I/0023    | 17_Change in specification of the medicinal product                                                                                                                                                                                                                                                                                               | 26/04/2000   | 04/05/2000   |             |                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0022   | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                   | 19/01/2000   | 22/02/2000   |             |                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0016   | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                  | 23/09/1999   | 20/01/2000   | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| I/0020   | 20_Extension of shelf-life as foreseen at time of authorisation                                    | 20/10/1999   | 13/12/1999   | SmPC   |                    |
|----------|----------------------------------------------------------------------------------------------------|--------------|--------------|--------|--------------------|
| I/0021   | 21_Change in shelf-life after first opening                                                        | 20/10/1999   | 04/11/1999   |        |                    |
| I/0019   | 24_Change in test procedure of active substance                                                    | 20/10/1999   | 04/11/1999   |        |                    |
| I/0018   | 15a_Change in IPCs applied during the manufacture of the product                                   | 20/10/1999   | 04/11/1999   |        |                    |
| I/0017   | 20a_Extension of shelf-life or retest period of the active substance                               | 20/10/1999   | 04/11/1999   |        |                    |
| I/0014   | 24a_Change in test procedure for starting material/intermediate used in manuf. of active substance | 08/02/1999   | n/a          |        |                    |
| I/0013   | 24a_Change in test procedure for starting material/intermediate used in manuf. of active substance | 08/02/1999   | n/a          |        |                    |
| I/0012   | 24a_Change in test procedure for starting material/intermediate used in manuf. of active substance | 08/02/1999   | n/a          |        |                    |
| I/0011   | 24a_Change in test procedure for starting material/intermediate used in manuf. of active substance | 08/02/1999   | n/a          |        |                    |
| I/0010   | 01_Change in or addition of manufacturing site(s) for manufacturing process                        | 08/02/1999   | n/a          |        | part or all of the |

<div style=\"page-break-after: always\"></div>

| I/0009   | change of manufacturing process of the substance                         | 23/09/1998   | 01/10/1998   | 12_Minor active   |
|----------|--------------------------------------------------------------------------|--------------|--------------|-------------------|
| I/0008   | 12_Minor change of manufacturing process of the active substance         | 23/09/1998   | 01/10/1998   |                   |
| I/0007   | 12_Minor change of manufacturing process of the active substance         | 23/09/1998   | 01/10/1998   |                   |
| I/0006   | 12_Minor change of manufacturing process of the active substance         | 23/09/1998   | 01/10/1998   |                   |
| I/0005   | 12_Minor change of manufacturing process of the active substance         | 23/09/1998   | 01/10/1998   |                   |
| I/0004   | 20a_Extension of shelf-life or retest period of the active substance     | 23/09/1998   | 01/10/1998   |                   |
| I/0003   | 16_Change in the batch size of finished product                          | 23/09/1998   | 01/10/1998   |                   |
| I/0002   | 08_Change in the qualitative composition of immediate packaging material | 23/09/1998   | 01/10/1998   |                   |
| I/0001   | 08_Change in the qualitative composition of immediate packaging material | 23/09/1998   | 01/10/1998   |                   |